DDIT3 and diffuse large B-cell lymphoma: Given the favorable safety profile of TAZ as a single agent, we conducted a phase Ib/II study Epi-R-CHOP (NCT02889523) to explore the safety and activity of combining TAZ with R-CHOP in elderly patients newly diagnosed with DLBCL.